KIORA PHARMACEUTICALS INC (KPRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.550.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KPRX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(12.6) + peer(0.2*-0.6) + term(0.0) → 4.29% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Conditions. On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Conditions. On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…
Results of Operations and Financial Conditions. On March 25, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…
Results of Operations and Financial Conditions. On November 7, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability…
Results of Operations and Financial Conditions. On August 8, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…
Results of Operations and Financial Conditions. On May 9, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2025 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that s…
Results of Operations and Financial Conditions. On March 25, 2025, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…
Results of Operations and Financial Conditions. On November 8, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability…
Results of Operations and Financial Conditions. On August 9, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…
Results of Operations and Financial Conditions. On May 10, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that…
Results of Operations and Financial Conditions. On March 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of tha…
Results of Operations and Financial Conditions. On November 9, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended September 30, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liab…
Results of Operations and Financial Conditions. On August 8, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended June 30, 2023 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability o…